The rare familial thrombocytopenic disorder Paris-Trousseau syndrome (PTS), reported in fewer than a dozen patients, is associated with inherited deletion of a portion of the long arm of chromosome 11 (1) . Blood platelets in affected individuals have a normal lifespan in the circulation; however, the number of bone marrow megakaryocytes is greatly increased, whereas megakaryocyte maturation is arrested, and many cells apparently fail to survive into terminal stages of differentiation (1, 2) . Together these findings suggest that platelet release is substantially impaired. Megakaryocyte release of newly synthesized platelets, a process unique to mammals, occurs through a dramatic morphogenetic transition (3, 4) . Nearly the entire cytoplasm converts into lengthy beaded projections (proplatelets), within which organelles are transported along unique microtubule tracks and nascent blood platelets assemble de novo (5) (Figure 1 ). The use of thrombopoietin, a megakaryocyte growth factor, to expand cells ex vivo and incisive mouse models of thrombocytopenia has led to rapid progress in understanding genetic and cellular mechanisms of platelet biogenesis (6); the emerging appreciation has important implications for diseases in which hemorrhage or thrombosis is a significant feature. In this issue of the JCI, Raslova and colleagues highlight transient monoallelic expression of a transcription factor gene en route to platelet release and explain why patients with PTS, who retain one normal copy of chromosome 11, produce few and defective platelets (7) . Related gene regulatory mechanisms might well account for other dominantly inherited disorders in which haploinsufficiency or interference with the wild-type product are inadequate explanations.
A transcriptional basis for PTS
Undeterred by the extreme rarity of PTS, Raslova et al. (7) have approached important questions raised by this unusual disorder. First, of the genes encoded within the 11q23-q24 deletion interval, the authors focused on the atypical ETS-family transcription factor FLI1 (8 influenced by the curious observation that PTS patients carry two discrete populations of megakaryocytes and platelets: many abnormally small megakaryocytes (micromegakaryocytes) and platelets (up to 15% of the total) that harbor giant α-granules and respond poorly to thrombin (1, 2). Reasoning that these morphologically distinct populations might derive from precursors in which FLI1 is expressed differentially at some point in the cellular ontogeny, they applied RNA-FISH and single-cell RT-PCR to demonstrate transient monoallelic FLI1 expression during a narrow window in megakaryocyte differentiation (Figure 1) . The results imply that hemizygous FLI1 loss in patients with PTS would leave some fraction of maturing megakaryocytes with too little FLI1, albeit transiently, a deficit that could result in the morphologic dichotomy and thrombocytopenia.
Figure 1
Schema of steps in megakaryocyte differentiation leading to platelet release in normal individuals and patients with PTS. Immature megakaryocyte progenitors, depicted on the left, acquire defining attributes (e.g., polyploidy) and surface markers (e.g., CD41) en route to a terminal step in which the cytoplasmic mass is converted into proplatelets and nascent blood platelets are assembled and released. Megakaryocytes expressing CD41 can be separated from more mature cells that also express the CD42 marker. Raslova et al. (7) propose that the transition between these two stages is marked by transient monoallelic expression of the FLI1 gene, an event that is presumed to result in normal cell differentiation, as illustrated in the top right branch of this figure. In PTS, where patients carry a multigene 11q deletion, absence of one FLI1 allele produces a population of megakaryocytes that is transiently devoid of any FLI1 transcription. The authors infer that it is this deficit that results in subpopulations of micromegakaryocytes and morphologically abnormal platelets as well as thrombocytopenia, as shown in the bottom right branch. The model potentially explains the genetic and major clinicopathologic features of PTS.
Monoallelic expression of autosomal genes is associated classically with genomic imprinting during embryogenesis or with allelic exclusion of surface receptor and selected cytokine genes in lymphocytes and olfactory neurons (13) (14) (15) (16) . However, rigorous demonstration of monoallelic gene expression requires methods that are not standard in most laboratories, so the extent of the phenomenon conceivably is underestimated. The 11q deletion in PTS can originate in either parent, and other disease features establish that FLI1 is not an imprinted locus. The observations of Raslova et al. (7) thus represent an apparently novel mechanism for transient regulation of a transcription factor gene. Before considering its significance and mechanisms, however, it is helpful to recall that previous demonstration of the same phenomenon for the Pax5 gene in B lymphocytes (17) is controversial (18) , largely because of the challenges in executing and interpreting single-cell RT-PCR reactions. It is therefore important to verify the FLI1 claim, ideally by examining protein levels at discrete stages in megakaryocyte maturation: depending on protein turnover rates, one prediction is that in individual wild-type CD41 + CD42 -megakaryocytes, FLI1 expression is halved, whereas some PTS-derived cells express no FLI1 at the same juncture. Another hypothesis that follows logically is that CD41 + megakaryocytes manifest an FLI1-dependent differentiation "checkpoint" somewhere along the transition that precedes CD42 expression (Figure 1) . If the Raslova model withstands further scrutiny, it raises very interesting questions. The mechanisms underlying transient monoallelic gene expression in this example are unknown and likely consist of some combination of the numerous epigenetic modifications that repress transcription. It is perhaps more interesting to ponder the possible reasons for a specialized cell to enable monoallelic gene expression during a brief period in its complex life cycle. Normally such regulation would merely adjust transcript levels; only in rare instances such as PTS would it produce unintended, deleterious consequences. One possibility is that FLI1 allelic exclusion reflects an adaptation of stochastic or pulsatile transcriptional activation, putative general features of gene regulation (19, 20) , which may transiently be skewed to physiologic advantage at selected loci. Regardless of the rationale and molecular mechanisms, monoallelic gene expression in mature megakaryocytes, which have a significantly polyploid DNA content, demands special consideration. Thus, the Raslova model implies that each of the 16 or more chromosome copies derived from one of the two original sets is epigenetically and selectively modified for transient silencing of some genes. Addressing these and related questions should stimulate research in both platelet biogenesis and gene regulatory mechanisms. The Raslova study thus illustrates how astute and dogged investigation of rare clinical disorders still carries the potential to reveal underlying principles in both normal and aberrant cellular physiology. Address correspondence to: Ramesh A. Shivdasani, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. Phone: (617) 632-5746; Fax: (617) 632-4471; E-mail: ramesh_shivdasani@dfci.harvard.edu.
